Dennis A. Hesselink

Dennis A. Hesselink

Auto-generated profile, based on publicly available information

Dennis A. Hesselink

Department of Internal Medicine Division of Nephrology and Transplantation Erasmus MC Rotterdam The Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2005 in American Journal of Transplantation
Verified
Journal Article
Closed access
PDF file
DHDennis A. Hesselink
Dennis A. Hesselink
RHReinier M. Van Hest
Reinier M. Van Hest
RMRon A. A. Mathot
Ron A. A. Mathot
FBFred Bonthuis
Fred Bonthuis
WWWillem Weimar
Willem Weimar
TGTeun van Gelder
Teun van Gelder

19 November 2013 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
DHDennis A. Hesselink
Dennis A. Hesselink
RBRachida Bouamar
Rachida Bouamar
LELaure Elens
Laure Elens
RSRon H. N. van Schaik
Ron H. N. van Schaik
TGTeun van Gelder
Teun van Gelder

1 December 2004 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
DHD Hesselink
D Hesselink
TVT Vangelder
T Vangelder
RVR Vanschaik
R Vanschaik
ABA Balk
A Balk
IVI Vanderheiden
I Vanderheiden
RMR Mathot
R Mathot

30 October 2017 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Open access
LALouise M. Andrews
Louise M. Andrews
YLYi Li
Yi Li
BWBrenda C. M. De Winter
Brenda C. M. De Winter
YSYun-Ying Shi
Yun-Ying Shi
Carla C. BaanCarla C. Baan
Carla C. Baan
DHDennis A. Hesselink
Dennis A. Hesselink
Introduction: Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy after solid organ transplantation and will probably remain so. Excluding belatacept, no new immunosuppressive drugs were registered for the prevention of acute rejection during the last decade. For several immunosuppressive drugs, clinical development halted because they weren’t sufficiently effective or more toxic. Areas covered: Current methods of monitoring Tac treatment, focusing on traditional therapeutic drug monitoring (TDM), controversies surrounding TDM, novel matrices, pharmacogenetic and pharmacodynamic monitoring are discussed. Expert opinion: Due to a narrow therapeutic index and large interpatient pharmacokinetic variability, TDM has been implemented for individualization of Tac dose to maintain drug efficacy and minimize the consequences of overexposure. The relationship between predose concentrations and the occurrence of rejection or toxicity is controversial. Acute cellular rejection also occurs when the Tac concentration is within the target range, suggesting that Tac whole blood concentrations don’t necessarily correlate with pharmacological effect. Intracellular Tac, the unbound fraction of Tac or pharmacodynamic monitoring could be better biomarkers/tools for adequate Tac exposure – research into this has been promising. Traditional TDM, perhaps following pre-emptive genotyping for Tac-metabolizing enzymes, must suffice for a few years before these strategies can be implemented in clinical practice.

7 April 2016 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Open access
JTJ.T. Tang
J.T. Tang
LAL.M. Andrews
L.M. Andrews
TGT. van Gelder
T. van Gelder
YSY.Y. Shi
Y.Y. Shi
RSR.H.N. van Schaik
R.H.N. van Schaik
DHD.A. Hesselink
D.A. Hesselink
Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and pharmacodynamics. Part of this is ex...